Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.
about
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineSulfatase 1 is an inhibitor of ductal morphogenesis with sexually dimorphic expression in the urogenital sinusERBIN deficiency links STAT3 and TGF-β pathway defects with atopy in humans.HIF-1-PHD2 axis controls expression of syndecan 4 in nucleus pulposus cells.Inhibition of PDGF-B induction and cell growth by syndecan-1 involves the ubiquitin and SUMO-1 ligase, ToporsHeparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progressionProteoglycans in Normal and Healing Skin.Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility.Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors.Wnt5a promotes cancer cell invasion and proliferation by receptor-mediated endocytosis-dependent and -independent mechanisms, respectively.Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1.Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsProteoglycans in cancer biology, tumour microenvironment and angiogenesis.Wnt and related signaling pathways in melanomagenesis.In the Wnt-er of life: Wnt signalling in melanoma and ageing.A spoonful of sugar makes the melanoma go: the role of heparan sulfate proteoglycans in melanoma metastasis.CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.Syndecans in cartilage breakdown and synovial inflammation.Targeting syndecans: a promising strategy for the treatment of cancer.Syndecans as modulators and potential pharmacological targets in cancer progression.Wnt Signaling Cascades and the Roles of Syndecan Proteoglycans.Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.Non-canonical Wnt signaling induces ubiquitination and degradation of Syndecan4Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells.Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells.Systematic classification of melanoma cells by phenotype-specific gene expression mapping.Dually modified transmembrane proteoglycans in development and disease.Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.[Transfer of autologous fat and plasma : The future of anti-aging medicine?].
P2860
Q26796247-92D68D04-84A1-4BD5-918E-12ED140FBD91Q28592245-067F0AD4-FA50-4951-BD3B-0048F86E4936Q30274910-EBD9BF69-4378-47E3-89FD-FFC69C40DA41Q30393730-16FFB5F6-8A62-44B4-AF9D-560BE2699A8FQ31086903-2957668D-F65E-4DE9-AE88-C8585D0AC013Q33924987-1DFC983E-FB2F-4483-8D8E-C499C4487BE7Q33965278-04FE7108-7C49-4C6E-9F88-15A5BACFCDDDQ34467680-350B2231-90F7-4C5E-9219-B79A345CD728Q34493922-2DF1E2D0-5BC7-4FE4-BC7B-56A2148958ACQ35158714-E36D4091-38BE-4B6E-8796-FC95D54050E9Q35549371-EBD573E9-0D15-4B13-B03E-353D5ECEEB43Q36339369-EB709831-3BDC-47F1-9C68-67D04FF534AFQ36545764-9AF7AB95-3614-4F74-873A-238B2EC79ABBQ36787608-B3AEE87D-4B59-4A6D-AE71-0104FCA8C3FDQ37328383-DAD048BC-0F08-481C-ADEE-8D31D79B2C3DQ37457229-FCED2177-4A98-4CA3-B29F-F10DA1CA5A50Q37943014-73848BD8-2C75-4FA5-B1AA-42321A0253CCQ37946449-127C285A-8B02-43AD-A3B0-8F29C676569CQ38054541-19D3263C-AB95-4D3A-B654-A5E6C6067390Q38082795-15E5C8FE-C9A2-46B3-B90D-FAA448061427Q38189392-1E943534-B654-4AEB-8AE2-74B7BF99CE35Q38441061-B89BCA0C-0F8E-430A-92CB-B17E488F5862Q38736415-D5653388-4EE9-49CB-BAF5-95C3F046E443Q39678821-C2C85FAC-7C28-41D2-950C-2795932EC8CEQ41375131-4D1A7105-0BD5-47D0-8A87-3175FF7D9270Q41444734-5E2A7BF0-266A-4980-A146-42CFB1C6D90CQ41901774-6FFC815C-1E63-4CDD-B691-40393AF333EBQ42818733-2912E754-FAB1-441F-AA73-47DD070C5716Q47240245-04446E5E-F434-4F8A-B62D-2E7B835086C5Q48823012-454D78D2-48F7-469F-9C5F-006200D0030CQ53630214-29F8E63E-6EE6-4C9E-BA52-FA4E7FA4EC40
P2860
Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@en
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@nl
type
label
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@en
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@nl
prefLabel
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@en
Heparan sulfate proteoglycan m ...... in metastatic melanoma cells.
@nl
P2093
P2860
P356
P1476
Heparan sulfate proteoglycan m ...... n in metastatic melanoma cells
@en
P2093
Ashani T Weeraratna
Brittany P Frank
Dennis D Taub
Emily K Kershner
Fred E Indig
Jennifer L Fiori
Keith S Hoek
P2860
P304
28704-28712
P356
10.1074/JBC.M109.028498
P407
P577
2009-08-20T00:00:00Z